Myocarditis following mRNA vaccination against SARS-CoV-2, a case series.

COVID-19 Myocarditis Myopericarditis Pericarditis mRNA vaccine

Journal

American heart journal plus : cardiology research and practice
ISSN: 2666-6022
Titre abrégé: Am Heart J Plus
Pays: United States
ID NLM: 101779333

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 02 07 2021
revised: 27 07 2021
accepted: 27 07 2021
entrez: 16 8 2021
pubmed: 17 8 2021
medline: 17 8 2021
Statut: ppublish

Résumé

mRNA COVID-19 vaccines have emerged as a new form of vaccination that has proven to be highly safe and effective against COVID-19 vaccination. Rare adverse events including myocarditis have been reported in the literature. Data were gathered from the electronic medical record of four patients personally treated by the authors. Four patients, ages 20 to 30, presented with myocarditis characterized by chest pain, elevations in troponin-I and C-reactive protein, and negative viral serologies two to four days following mRNA vaccine administration. One had a cardiac MRI showing delayed gadolinium enhancement in a subpericardial pattern. All experienced symptom resolution by the following day, and the two who have returned for follow-up had normal troponin-I and CRP values. Along with previously reported instances, these cases raise suspicion for a possible link between mRNA vaccines and myocarditis.

Identifiants

pubmed: 34396358
doi: 10.1016/j.ahjo.2021.100042
pii: S2666-6022(21)00040-9
pmc: PMC8349733
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100042

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

JAMA. 2003 Jun 25;289(24):3283-9
pubmed: 12824210
Pediatrics. 2021 Sep;148(3):
pubmed: 34088762
Vaccine. 2021 Jun 29;39(29):3790-3793
pubmed: 34092429
Radiol Case Rep. 2021 Aug;16(8):2142-2145
pubmed: 34025885
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Med. 2021 Jun;27(6):1062-1070
pubmed: 33888900
BMJ. 2021 Jun 14;373:n1435
pubmed: 35727911
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Vaccine. 2021 Jan 29;39(5):839-845
pubmed: 33422381

Auteurs

William W King (WW)

Department of Internal Medicine, University of Florida, 1600 SW Archer Road, Room 4102, Gainesville, FL 32610-0277, United States of America.

Matthew R Petersen (MR)

Department of Internal Medicine, University of Florida, 1600 SW Archer Road, Room 4102, Gainesville, FL 32610-0277, United States of America.

Ralph M Matar (RM)

Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, United States of America.

Jeffery B Budweg (JB)

Department of Internal Medicine, University of Florida, 1600 SW Archer Road, Room 4102, Gainesville, FL 32610-0277, United States of America.

Lyda Cuervo Pardo (L)

Division of Rheumatology and Clinical Immunology, University of Florida, Gainesville, FL, United States of America.

John W Petersen (JW)

Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, United States of America.

Classifications MeSH